Great Basin Scientific Announces 201 Customers To End January 2016

Company focuses on under-served hospital laboratories with its easy-to-use, low-cost, and versatile system for molecular diagnostics

SALT LAKE CITY--(BUSINESS WIRE)--Great Basin Scientific, Inc. (NASDAQ:GBSN) announced today that its customer base grew to 201 sites by the end of January, up from 186 at the end of December 2015, continuing the Company’s steady overall growth for its sample-to-result molecular diagnostics platform.

“We’re pleased to have reached this milestone and gratified to be able to support hospitals like Towner County Medical Center”

Great Basin’s platform is designed to meet the needs of the small, mid-sized, and critical access hospitals. With limited capital equipment budgets and a need for simplified workflow, smaller hospitals have historically been challenged to adopt molecular diagnostics. Great Basin places their analyzer in hospitals at no cost and delivers ease of use, allowing hospitals to quickly and easily adopt fast and accurate molecular diagnostics.

“I appreciate Great Basin’s products and customer service. They are allowing us little guys to perform testing we never would have been able to before their solution,” said Tabatha Halvorson, Lab Director at Towner County Medical Center in Cando, N.D. and a new Great Basin customer. “The impact this will have on quality of patient care is very exciting.”

Commercially available tests from Great Basin include low-plex tests for Clostridium difficile (C. diff) and Group B Streptococcus (GBS). The Company is awaiting 510(k) clearances from the U.S. Food & Drug Administration (FDA) for their Shiga Toxin Direct Test, which, upon FDA clearance, will be the only stand-alone test to provide CDC-recommended identification of the high-virulence serotype O157 in conjunction with the Shiga toxin-producing E. coli (STEC) detection; and Staph ID/R Blood Culture panel, a direct from whole blood multiplex panel to detect blood sepsis caused by MRSA and other staph species.

“We’re pleased to have reached this milestone and gratified to be able to support hospitals like Towner County Medical Center,” said Ryan Ashton, co-founder and Chief Executive Officer of Great Basin Scientific.

About Great Basin Scientific

Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company’s vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the company’s website at www.gbscience.com.

Forward-Looking Statements

This press release includes forward-looking statements regarding the Company’s continuing business efforts related to its products, including but not limited to, assistance of health providers to define a clear treatment path sooner for improved patient outcomes, shorter hospital stays and dollars saved in hospitalization costs per patient, the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases and related statements. Forward-looking statements involve risk and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risk and uncertainties include, but are not limited to: (i) our limited operating history and history of losses; (ii) our ability to develop and commercialize new products and the timing of commercialization; (iii) our ability to obtain capital when needed; and (iv) other risks set forth in the Company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015. These forward-looking statements speak only as of the date hereof and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.